Aflac Incorporated (AFL) is a supplemental health and life insurer operating through two main segments: Aflac Japan and Aflac U.S. Founded in 1955 and headquartered in Columbus, Georgia, the company is best known for its cancer, accident, and disability policies. With shares recently trading near $116, the question of whether the stock can climb toward $138 — the highest 12-month analyst price target on Wall Street — has become a focal point for investors.
That $138 figure stands out because it sits well above the broader consensus. According to data aggregators, roughly 15 analysts track the stock, and the average price target is only about $118, implying modest upside from current levels. Reaching $138 would therefore require Aflac to outperform the expectations of most sell-side analysts, not merely meet them.
Aflac trades with a price-to-earnings (P/E) ratio around 12 to 13 times trailing earnings and a forward P/E near 16 times, reflecting a premium to its own historical median of roughly 10 times. The stock carries a beta near 0.60, meaning it has historically been less volatile than the broader market — a characteristic that cuts both ways, providing downside protection in weak markets but limiting outsized gains during rallies.
The company's dividend remains a pillar of its investment case. Aflac recently raised its quarterly payout to $0.61 per share, and the forward yield is just above 2%. Management has also remained an aggressive repurchaser of shares, which supports earnings per share (EPS) growth even when revenue is flat or declining.
Several factors would need to align for Aflac to approach $138. First, the company would need to stabilize its top line. Revenue has been under pressure in recent quarters, driven in part by the Japan segment and foreign-exchange headwinds. A durable recovery in Japan sales — or a weakening U.S. dollar — would remove a significant drag on reported results.
Second, continued capital returns matter. Aggressive buybacks and consistent dividend growth can support per-share metrics and, over time, justify a higher multiple. Third, the broader life and health insurance sector has benefited from a generally constructive environment for carriers, including solid underwriting trends and healthy investment income. If that favorable backdrop persists, it could support a re-rating.
Notably, several firms have nudged their targets higher in recent months. MetLife (MET) and other insurance peers have at times shown correlated strength, and upward revisions from analysts at Raymond James, KBW, and Morgan Stanley reflect a modestly more constructive tone, even as the overall consensus remains neutral.
The most significant obstacle is growth. Aflac's revenue has been declining modestly, and consensus estimates project continued softness in the near term. A company with shrinking top-line revenue typically struggles to sustain multiple expansion, and reaching $138 would likely require meaningful multiple expansion beyond the stock's historical range.
Valuation is a related concern. Several analysts, including those at Mizuho and Wolfe Research, have assigned Sell or Underperform ratings, arguing the stock trades at a premium that is difficult to justify given muted growth prospects. Heavy insider selling reported in recent months has also been flagged as a cautionary signal by some market observers.
Japan remains a structural challenge. The country's aging and shrinking population limits long-term policy growth, and currency fluctuations can distort reported earnings. Any renewed strength in the U.S. dollar would further pressure results.
From a technical analysis standpoint, Aflac's 52-week high near $130.22 represents the most important resistance level to watch. The stock would first need to clear that prior peak before $138 even comes into play. On the downside, the $104 to $105 area has provided support over the past year. A failure to hold above current levels near $116 could bring the $110 zone — a level cited in several analyst reports — back into focus.
For traders seeking a more dynamic view of Aflac and thousands of other securities, Tickeron's AI Daily Buy/Sell Signals provide a data-driven way to track shifting conditions. The product uses artificial intelligence to continuously monitor stocks and exchange-traded funds (ETFs), generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Investors can use these signals to discover new opportunities, monitor existing positions, and identify evolving market trends more efficiently than manual screening alone. Traders interested in a systematic, AI-assisted approach to the market may find these signals a useful addition to their research process.
Can Aflac reach $138? The target is not out of reach, but it is ambitious relative to the broader analyst consensus, which sits near $118. The stock's defensive characteristics, reliable dividend, and active buybacks provide a solid foundation, and sector tailwinds could support a gradual move higher. However, persistent revenue declines, Japan-related headwinds, and a valuation that many analysts consider stretched make a push toward $138 dependent on multiple expansion and improved growth — conditions that have yet to materialize.
Investors should monitor Japan segment performance, foreign-exchange trends, and any evidence of revenue stabilization. The path to $138 likely requires Aflac first to reclaim and hold its prior high near $130, then to demonstrate the kind of earnings acceleration that would justify a richer valuation. Until those conditions appear, the $138 target should be viewed as a longer-term, higher-conviction scenario rather than a near-term certainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AFL has been loosely correlated with CNO. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if AFL jumps, then CNO could also see price increases.